Search

Researchers at the University of Bonn in Germany have succeeded in finding a potentially low-cost source of a potent antiviral compound known to prevent replication of the HIV virus in vitro.

Last month the world's leading pharmaceutical company received simultaneous FDA approval for two new therapies. Yet neither drug was invented by the company. Both were originally developed by small biotechs.

The founding dean of INSEAD's Singapore campus is moving to the UK to head up the Judge Business School at Cambridge.

TU Delft ditched the usual model of outlicensing or seeking venture capital backing when it was looking to commercialise a novel wastewater treatment technology.

Dental implant company Neoss Ltd raised £5 million in its third funding round, enabling it to further develop the technology and expand its sales and marketing operations.

A pre-designed biomanufacturing facility with advance planning permission is the latest carrot devised by the Industrial Development Authority (IDA) Ireland in its efforts to attract international biopharmaceutical manufacturing projects.

Researchers at the Advanced Technology Institute at the University of Surrey recently reported that they have shown and observed a phenomenon called negative differential resistance - holding out the prospect of a new generation of cheap and fast semiconductors.

The UK's stem cell community has reacted with collective dismay at the final confirmation that Hwang Woo-suk's claims to have generated patient-specific embryonic stem cell lines were fraudulent. Nuala Moran takes a look.

The concept of angel investing - in which individuals devote both their time and money to nurturing young companies - has evolved over the past decade from an unknown or poorly understand phenomena in many parts of Europe to an established form of finance.

Venture capital firms used to moan that business angels were unprofessional and hard to work with. But Europe's new breed of angel investor networks appears anything but that, says Mary Lisbeth D'Amico

Marc Van Montagu, Europe's founding father of genetically modified crops and a powerful advocate for their acceptance in Europe, speaks to Science|Business News Editor Thomas Lau.

Lein Applied Diagnostics, a British company that develops blood glucose measuring for people with diabetes, has announced it has received further investment from its shareholder Seven Spires Investments. The company is seeking more investment to put a non-invasive blood glucose meter into clinical trials.

Spanish researchers have developed a technology that allows even the tone deaf to pick music with the right rhythm and tempo to keep the mass swaying.

Micromet AG, a spin-off from the Institute for Immunology at Munich University, said it has agreed to grant four licenses of its single chain antibody technology to Abbott Laboratories, Alligator Bioscience AB, Haptogen Ltd. and an unnamed biopharmaceutical company, for the development of cancer treatments.

Lipoxen Plc, a drug spin-out company from the University of London's School of Pharmacy, said it has raised £3.78 million from a placing of 28 million shares for hiring news staff for preclinical trials to treat diabetes, Pneumococcal infections, and hepatitis C.